Irvine, USA- Masimo, a global leader in innovative monitoring technologies, has achieved FDA clearance for Stork™, an advanced baby monitoring system designed for prescription use with babies aged 0-18 months. Utilizing Masimo’s proven sensor technology, the same trusted by hospitals for over 10 million babies annually, Stork offers continuous and precise monitoring of a baby’s health. While available nationwide for general health and wellness as a non-medical device, Stork’s FDA clearance now enables its prescription use for at-home medical monitoring of both healthy and sick babies.
Stork’s technology, known as Signal Extraction Technology ® (SET ®), has a proven track record in neonatal intensive care units, aiding in reducing neonatal blindness and enhancing screening for critical congenital heart disease. Stork’s performance specifications, notably its SpO2 accuracy, make it a reliable choice even during a baby’s movement.
The Stork Vitals+ bundle features a sleek design with a medical-grade silicone boot housing the innovative sensor....READ MORE
Irvine, USA- Masimo, a global leader in innovative monitoring technologies, has achieved FDA clearance for Stork™, an advanced baby monitoring system designed for prescri...
A virtual marketplace leading your business into the future
